House panel to investigate GM recall of part linked to fatal crashes

WASHINGTON -- A House committee has launched an investigation into how General Motors Corp. and federal regulators handled the recall of vehicles with a malfunctioning ignition switch that led to at least 13 traffic deaths.

As part of the probe, the House Energy and Commerce Committee will hold a hearing in the coming weeks to determine if there was a delay in GM's recall of 1.6 million vehicles with the faulty part, Rep. Fred Upton (R-Mich.), the panel's chairman, said Monday night.

The committee also will look into the response of the National Highway Traffic Safety Administration was slow to respond to the problem in the face of consumer complaints.

PHOTOS: Highlights of the 2014 Geneva Motor Show

Agency documents show GM knew of the ignition-switch defect as far back as 2004 but didn't issue the recall until last month.

"Did the company or regulators miss something that could have flagged these problems sooner?" Upton said.

"If the answer is yes, we must learn how and why this happened, and then determine whether this system of reporting and analyzing complaints that Congress created to save lives is being implemented and working as the law intended," he said.

Upton sponsored legislation, enacted in 2000, designed to get automakers and regulators to move quicker to recall vehicles and parts with safety defects.

The Transportation Recall Enhancement, Accountability, and Documentation Act, known as the TREAD Act, came in response to committee hearings into Firestone tire failures on Ford Explorers.

Auto safety experts have criticized GM and the NHTSA for not acting quicker to deal with the ignition-switch problem

The NHTSA is investigating GM's handling of the issue. The automaker could be fined as much as $35 million.

Last week, GM Chief Executive Mary Barra said the company would conduct a thorough review of whether it delayed a recall.


Betty Ford Center ready for a comeback

Americans are drinking less coffee daily, study says

U.S. lawmakers ask Gilead to justify hepatitis C drug's $84,000 price

Copyright © 2018, The Baltimore Sun, a Baltimore Sun Media Group publication | Place an Ad